in vitro activities of six antifungal drugs against candida glabrata isolates: an emerging pathogen

results the sequence analysis of the isolate confirmed as c. glabrata and deposited on ncbi genbank under the accession number no. kt763084-kt763123. the geometric mean mics against all the tested strains were as follows, in increasing order: casp (0.17 g/ml), vcz (0.67 g/ml), amb (1.1 g/ml), itz (1.82 g/ml), ktz (1.85 g/ml), and fcz (6.7 g/ml). the resistance rates of the isolates to casp, fcz, itz, vz, ktz, and amb were 5%, 10%, 72.5%, 37.5%, 47.5%, and 27.5%, respectively. conclusions these findings confirm that casp, compared to the other antifungals, is the potent agent for treating candidiasis caused by c. glabrata. however, the clinical efficacy of these novel antifungals remains to be determined. background candida glabrata is a pathogenic yeast with several unique biological features and associated with an increased incidence rate of candidiasis. it exhibits a great degree of variation in its pathogenicity and antifungal susceptibility. objectives the aim of the present study was to evaluate the in vitro antifungal susceptibilities of the following six antifungal drugs against clinical c. glabrata strains: amphotericin b (amb), ketoconazole (ktz), fluconazole (fcz), itraconazole (itz), voriconazole (vcz), and caspofungin (casp). materials and methods forty clinical c. glabrata strains were investigated using dna sequencing. the in vitro antifungal susceptibility was determined as described in clinical laboratory standard institute (clsi) documents (m27-a3 and m27-s4).